Literature DB >> 21083255

Accelerator mass spectrometry best practices for accuracy and precision in bioanalytical (14)C measurements.

John S Vogel1, Jason A Giacomo, Tim Schulze-König, Bradly D Keck, Peter Lohstroh, Stephen Dueker.   

Abstract

Accelerator mass spectrometers have an energy acceleration and charge exchange between mass definition stages to destroy molecular isobars and allow single ion counting of long-lived isotopes such as (14)C (t½=5370 years.). 'Low' voltage accelerations to 200 kV allow laboratory-sized accelerator mass spectrometers instruments for bioanalytical quantitation of (14)C to 2-3% precision and accuracy in isolated biochemical fractions. After demonstrating this accuracy and precision for our new accelerator mass spectrometer, we discuss the critical aspects of maintaining quantitative accuracy from the defined biological fraction to the accelerator mass spectrometry quantitation. These aspects include sufficient sample mass for routine rapid sample preparation, isotope dilution to assure this mass, isolation of the carbon from other sample combustion gasses and use of high-efficiency biochemical separations. This review seeks to address a bioanalytical audience, who should know that high accuracy data of physiochemical processes within living human subjects are available, as long as a (14)C quantitation can be made indicative of the physiochemistry of interest.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21083255     DOI: 10.4155/bio.10.13

Source DB:  PubMed          Journal:  Bioanalysis        ISSN: 1757-6180            Impact factor:   2.681


  4 in total

1.  New frontiers-accelerator mass spectrometry (AMS): Recommendation for best practices and harmonization from Global Bioanalysis Consortium Harmonization Team.

Authors:  Graeme C Young; Mark Seymour; Stephen R Dueker; Philip Timmerman; Ali Arjomand; Kohei Nozawa
Journal:  AAPS J       Date:  2014-02-06       Impact factor: 4.009

2.  Pharmacokinetics of 2-phenoxyethanol and its major metabolite, phenoxyacetic acid, after dermal and inhaled routes of exposure: application to development PBPK model in rats.

Authors:  Mihye Kwon; Jung Bae Park; Miwha Kwon; Jinho Song; Chang Su Yeo; Soo Hyeon Bae
Journal:  Arch Toxicol       Date:  2021-04-12       Impact factor: 5.153

Review 3.  Mini-Review: Comprehensive Drug Disposition Knowledge Generated in the Modern Human Radiolabeled ADME Study.

Authors:  Douglas K Spracklin; Danny Chen; Arthur J Bergman; Ernesto Callegari; R Scott Obach
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2020-07-31

4.  Open-label, single-center, phase I trial to investigate the mass balance and absolute bioavailability of the highly selective oral MET inhibitor tepotinib in healthy volunteers.

Authors:  Andreas Johne; Holger Scheible; Andreas Becker; Jan Jaap van Lier; Peter Wolna; Michael Meyring
Journal:  Invest New Drugs       Date:  2020-03-27       Impact factor: 3.850

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.